Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences has reported Change in Accured Expenses over the past 6 years, most recently at $4.8 million for Q3 2022.

  • Quarterly results put Change in Accured Expenses at $4.8 million for Q3 2022, up 189.58% from a year ago — trailing twelve months through Sep 2022 was $16.5 million (up 218.03% YoY), and the annual figure for FY2021 was $8.4 million, up 81.91%.
  • Change in Accured Expenses for Q3 2022 was $4.8 million at Arcus Biosciences, up from $2.9 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for RCUS hit a ceiling of $14.3 million in Q3 2020 and a floor of -$19.1 million in Q4 2020.
  • Median Change in Accured Expenses over the past 5 years was $1.4 million (2018), compared with a mean of $1.5 million.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1209.05% in 2018 and later tumbled 11371.43% in 2020.
  • Arcus Biosciences' Change in Accured Expenses stood at -$2.3 million in 2018, then skyrocketed by 73.84% to -$593000.0 in 2019, then plummeted by 3116.19% to -$19.1 million in 2020, then soared by 117.16% to $3.3 million in 2021, then surged by 46.9% to $4.8 million in 2022.
  • The last three reported values for Change in Accured Expenses were $4.8 million (Q3 2022), $2.9 million (Q2 2022), and $5.6 million (Q1 2022) per Business Quant data.